In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Viridian Therapeutics (VRDN – Research Report), with a price target of $44.00. The company’s shares closed last Thursday at $17.09.
According to TipRanks.com, Butler is a 3-star analyst with an average return of 5.2% and a 43.2% success rate. Butler covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Aquestive Therapeutics, and ACADIA Pharmaceuticals.
Currently, the analyst consensus on Viridian Therapeutics is a Strong Buy with an average price target of $37.20, representing a 124.2% upside. In a report issued on October 12, Evercore ISI also initiated coverage with a Buy rating on the stock with a $40.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Viridian Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.09 million and GAAP net loss of $17.96 million. In comparison, last year the company earned revenue of $168K and had a GAAP net loss of $6.44 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.
Read More on VRDN:
